Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 31, 2013
For more info, visit http://www.bio-rad.com/yt/4/QX200-Dro.... Droplet Digital PCR (ddPCR™) technology is being used to identify cancer subtypes, optimize drug treatment plans, monitor residual disease, and study tumor evolution. ddPCR assays offer advantages in the field of liquid biopsies, enablingto the measurement of circulating nucleic acids (cfDNA) and circulating tumor cells (CTCs) in blood. ddPCR can detect rare tumorigenic mutations in a high background of normal DNA, routinely down to 0.01% and often further. Dr Dawne Shelton discusses the techniques and methods that will enable you to begin your own investigations.
The QX200™ Droplet Digital PCR system, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.
Presenter: Dawne Shelton PhD, Senior Scientist Dr. Shelton earned her PhD in oncological sciences from the University of Utah, Huntsman Cancer Institute. She has investigated different aspects of the Wnt pathway in colon cancer, studied the origins of the different subtypes of breast cancer, and examined uterine cancer in a clinical cancer research lab. She is now a senior scientist at the Digital Biology Center at Bio-Rad Laboratories, focusing on developing applications and collaborations for ddPCR in the cancer field.
Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.